NAMS
NewAmsterdam Pharma Company N.V.
$38.27
+$0.56(+1.49%)
70
Overall
50
Value
91
Tech
--
Quality
Market Cap
$4.41B
Volume
1.46M
52W Range
$14.06 - $41.47
Target Price
$45.92
Company Overview
| Mkt Cap | $4.41B | Price | $38.27 |
| Volume | 1.46M | Change | +1.49% |
| P/E Ratio | -18.3 | Open | $37.65 |
| Revenue | $45.6M | Prev Close | $37.71 |
| Net Income | $-241.6M | 52W Range | $14.06 - $41.47 |
| Div Yield | N/A | Target | $45.92 |
| Overall | 70 | Value | 50 |
| Quality | -- | Technical | 91 |
No chart data available
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
NewAmsterdam Pharma Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•17 days ago
NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone
TipRanks Auto-Generated Newsdesk•18 days ago
NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $38.27 | +1.5% | 1.46M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW